Back to results
US 2016/0354420 A1Published application
Oncolytic Adenoviruses for Cancer Treatment
AssigneeDnatrix, Inc.
InventorsRamon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
Life of this patent
Estimating the term…
Abstract
The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
Claims13
An oncolytic adenovirus to treat cancer, the adenovirus comprising:
- an E1a gene, the E1a gene comprising a delta-24 mutation;
- a tumor selective promoter upstream of the E1a gene that confers tumor selective expression of the E1a gene;
- and a myotonic dystrophy insulator upstream of the promoter that comprises a sequence encoding a CTCF binding site and insulates the promoter against transcriptional interference.
Dependencies are inferred from the claim text.